Interleukin-23 Inhibitors (IL-23i)

PreclinicalSmall molecule

SSixth Affiliated Hospital, Sun Yat-sen University

Interleukin-23 Inhibitors (IL-23i) is one of 39 small molecule programs targeting Inflammatory Bowel Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Inflammatory Bowel DiseaseActive, not recruiting

Inflammatory Bowel DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

151 competitors in Inflammatory Bowel Disease

#DrugCompanyPhaseTrials

Remicade

OOrganon and Co

Phase 3

17 2

Thalomid

Bristol-Myers Squibb

Phase 3

1 3

Stelara

Johnson & Johnson

Phase 3

1 4

Farxiga

AstraZeneca

Phase 3

1 5

Humira

CCelltrion

Phase 3

7 6

Omvoh

Eli Lilly

Phase 3

—7

Valcyte

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 8

Deltavit

HHyundai Pharmaceutical Co., LTD.

Jyseleca

1 10

Iron Sulphate

PPierre Fabre Pharma GmbH

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Not yet recruiting

Inflammatory Bowel Disease

NCT07184138

Clinical

Trials by Indication[1]

Inflammatory Bowel Disease1 trial

Real-World Study on the Safety and Effectiveness of IL-23 Inhibitors for Inflammatory Bowel Disease in China

Not yet recruiting·SSixth Affiliated Hospital, Sun Yat-sen University··NCT07184138·178 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Interleukin-23 Inhibitors (IL-23i). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Interleukin-23 Inhibitors (IL-23i) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Interleukin-23 Inhibitors (IL-23i). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sixth Affiliated Hospital, Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSixth Affiliated Hospital, Sun Yat-sen University

Interleukin-23 Inhibitors (IL-23i)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Inflammatory Bowel Disease1 trial

References

Drug Info

Quick Facts

Related News